28-06-2025
Nuvama Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Aurobindo Pharma Ltd (AUROPHARMA – Research Report), with a price target of INR1,460.00. The company's shares closed yesterday at INR1,121.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited.
Currently, the analyst consensus on Aurobindo Pharma Ltd is a Moderate Buy with an average price target of INR1,430.00.
Based on Aurobindo Pharma Ltd's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR83.82 billion and a net profit of INR9.03 billion. In comparison, last year the company earned a revenue of INR75.8 billion and had a net profit of INR9.09 billion
